HCL, Eli Lilly open Co-Innovation Lab in Singapore

Global pharmaceutical corporation, Eli Lilly, and HCL Technologies Ltd (HCL today announced the opening of a Co-Innovation Lab in Singapore. The lab would develop novel technologies to improve operational efficiencies and enhance Eli Lilly's global competitiveness.

The unique collaboration, the first of its type for both companies globally would accelerate the process of bringing ideas to fruition by leveraging this Co-Innovation lab and HCL's wider collaborative ecosystem, using new disruptive technologies and solutions. 

The two companies plan to incubate innovative ideas and concepts with the establishment of a framework for collaboration. The aim is to track technology trends and create 'proofs of concept' (PoCs) for applied solution frameworks. Learning would be sourced from experiences across multiple industries including: banking, government, insurance, manufacturing, telecom as well as pharmaceuticals.

HCL would leverage state-of-the-art technologies including cloud computing, automation, business analytics, enterprise mobility and others combined with its domain expertise in numerous areas to create innovative applications and solutions to support Eli Lilly's global operations.

Co-Innovation is expected to help the two companies to extend the scale and scope of external partnerships and alliances and these in turn would bring new ideas in the form of technology and knowledge to the market.

The laboratory, which would act as a key component of Eli Lilly's IT Innovation strategy, was inaugurated by Michael C Heim, senior vice president and chief information officer, Eli Lilly and Company.